News of Note—ILiAD Biotechnologies, Emergex and more

Here is some other vaccine news of note for the week:

> ILiAD Biotechnologies announced that the National Institute for Allergy and Infectious Diseases submitted an Investigational New Drug application to study its next-gen pertussis vaccine. Release

> U.K. biotech Emergex picked up a £979,318 ($1.32 million) grant from Innovate UK to advance universal flu vaccine work. Release

> The former chief scientific officer of Moderna's vaccine division, Giuseppe Ciaramella, joined CRISPR startup Beam Therapeutics. Chemical & Engineering News article